)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Haisco Pharmaceutical Group
Haisco Pharmaceutical Group (002653) investor relations material
Haisco Pharmaceutical Group Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
9M revenue rose 50.61% YoY to ¥4.970bn, while attributable net income increased 314.01% to ¥1.376bn; BD income, drug sales and collaboration product sales supported growth.
Q3 revenue grew 44.30% YoY; attributable net income advanced 207.26% to ¥525.25m.
9M operating cash flow reached ¥1.051bn, up 170.10% YoY.
Financial highlights
9M adjusted net income, excluding non-recurring items, was ¥1.265bn, up 263.22% YoY; Q3 adjusted net income was ¥512.9m, up 200.01%.
9M total costs and expenses were ¥3.640bn; R&D expense rose 67.98% to ¥911.1m and administrative expense increased 35.45% to ¥419.5m.
Other income increased 349.02% to ¥122.5m, mainly due to industrial support funds from the Shannan Investment Promotion Bureau.
9M non-recurring gains totaled ¥111.4m, including ¥106.1m in government grants.
Segment performance
Revenue growth was attributed to higher BD business income, continued growth in finished-drug sales, and increased collaboration product sales.
BD-related collections contributed to higher cash receipts from product sales and services, which increased 41.59% YoY to ¥4.693bn in 9M.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Haisco Pharmaceutical Group
- Net profit jumped 426.98% to ¥851 million on 54.71% revenue growth, fueled by innovation and global deals.002653
Q2 2026 - H1 2024 revenue up 23.14%, net profit up 119.40%, led by innovative drug growth.002653Q2 2024
- Net profit surged 34% on double-digit revenue growth and strong innovative drug sales.002653Q4 2024
- Net profit nearly doubled year-over-year on higher revenue, asset sales, and new product launches.002653Q3 2024
- Revenue up 17.91% to ¥4.39B, net profit down 34.36%, R&D spend at ¥1.08B.002653Q4 2025
- Net value rose 17.63% in H1 2025, led by Hong Kong equities and strong risk controls.002653Q2 2025
- Revenue up 18.60% but net profit down 49.31% year-over-year amid higher R&D and lower subsidies.002653Q1 2025
- Revenue up 22% but net profit down 23% in Q3 2025 amid surging R&D and lower subsidies.002653Q3 2025
- Net profit surged over 1,000% year-over-year on strong technology transfer income.002653Q1 2026
Next Haisco Pharmaceutical Group earnings date
Q4 202612 Apr, 2027
Haisco Pharmaceutical Group
Next Haisco Pharmaceutical Group earnings date
Q4 202612 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)